(OSI) Eyetech Pharmaceuticals Inc. and Pfizer Inc. have initiated a phase IV trial that will study whether use of pegaptanib sodium injection (Macugen) following neovascular age-related macular degeneration (AMD) therapy provides a balance in long-term safety and efficacy. Called LEVEL (EvaLuation of Efficacy and safety in maintaining Visual acuity with sEquential treatment of neovascuLar AMD), the 54-week trial will comprise up to 1,000 patients at 100 sites across the country.
The use of hormonal therapies may represent the next generation of medication for the tear film deficiencies of dry eye.
The femtosecond pulses offer real, precise subsurface effects, with the least amount of energy required.
San Francisco—Studies with the accommodating IOL (crystalens, eyeonics) are providing new insights regarding its mechanism of action that help to explain why some patients have achieved near vision that is much better than expected.
The FDA approved WaveLight Inc.'s wavefront-optimized Allegretto Wave excimer laser system for the treatment of mixed astigmatism. The indication is to reduce or eliminate naturally occurring mixed astigmatism of up to 6 D at the spectacle plane.
Overall, acute endothelial cell loss rates were about 6% for both
the central and peripheral cornea.
Farmers Branch, TX—Corporate, state, and local officials
joined together recently to break ground on Essilor of America's
new U.S. corporate campus. Development of the campus is planned as
a 5-year process. Phase one will redevelop existing structures and
construct new buildings to create 270,000 square feet of space.